The medical technology sector is facing a potential setback due to the Australian Labor Party's (ALP) recent overhaul of capital gains tax (CGT) regulations. This move has sparked concerns among health startups and industry bodies, who argue that the changes could hinder the growth and development of medical technology companies in Australia.
The ALP's budget changes include a ten-year limit on a component of the research and development (R&D) tax incentive, which allows companies to claim refunds for losses incurred during the research phase. This is particularly problematic for health startups, as it takes them longer to bring products to market compared to other industries. The letter sent to Treasurer Jim Chalmers by nine peak health and medical technology industry bodies highlights the 'triple threat' posed by these changes, emphasizing the potential negative impact on the sector.
One of the key issues is the removal of R&D 'supporting activities' from eligibility, which affects clinical, regulatory, and quality services that are often outsourced by startups due to cost constraints. This limitation could put Australia's world-class health and medical research support organizations at risk, as they play a crucial role in the development process. The industry bodies argue that this change, combined with the CGT overhaul, may discourage companies from pursuing high-risk R&D, potentially impacting their decision to stay in Australia.
The CGT changes have already caused uncertainty for Australian companies, especially those making long-term decisions about clinical developments. Biotech developers feel 'blindsided' by the ALP's approach, as the sector has become a significant export industry, supporting over 350,000 jobs across almost 3,000 organizations. The Shadow Treasurer, Tim Wilson, and Shadow Health Minister, Anne Ruston, have expressed similar concerns, warning that the tax changes could negatively impact innovation and investment in medical technology.
The ALP has acknowledged the potential issues and is consulting with the tech sector and startups to explore carve-outs for the CGT changes. However, the rapid pace of the legislation has been criticized, with business groups demanding significant amendments. Prime Minister Anthony Albanese has ruled out a lengthy process, emphasizing the need for good-faith engagement in the detailed design of the legislation.
The future of medical technology in Australia remains uncertain as the industry grapples with these tax changes. The sector's reliance on R&D incentives and the potential impact on innovation and investment are critical factors that will shape the industry's trajectory. As the consultations continue, the industry bodies and startups eagerly await the government's response and the final shape of the tax regime.
